Myriad Genetics, Inc. MYGN
5.67 USD -0.07 (-1.22%)
At closeNov 10, 2026, 4:00 PM EST
5.67 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
5.55 Day range 5.75
2.74 52-week range 8.09
- YTD
- -7.80%
- 1 year
- -12.50%
News
seekingalpha.com Myriad Genetics, Inc. (MYGN) Presents at 2026 UBS Global Healthcare Conference Transcript Myriad Genetics, Inc. ( MYGN ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal…
benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $6.75 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4.5 to $6.75.
benzinga.com Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8 Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.
seekingalpha.com Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript Myriad Genetics, Inc. ( MYGN ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO &…
zacks.com Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates Myriad Genetics (MYGN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to break-even earnings per share a year ago.
marketbeat.com Myriad Genetics Q3 Earnings Call Highlights Myriad Genetics NASDAQ: MYGN reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal…
benzinga.com Myriad Genetics Q3 2026 Earnings Call Transcript Myriad Genetics (NASDAQ:MYGN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Myriad Genetics Raises FY2026 Sales Guidance from $770.000M-$790.000M to $780.000M-$790.000M vs $777.921M Est Myriad Genetics (NASDAQ:MYGN) raises FY2026 sales outlook from $770.000 million-$790.000 million to $780.000 million-$790.000 million vs $777.921 million estimate.
benzinga.com Myriad Genetics Q3 Adj. EPS $(0.11) Beats $(0.20) Estimate, Sales $202.700M Beat $191.329M Estimate Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. The company reported quarterly sales of $202.700…
globenewswire.com Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
benzinga.com Nasdaq Rises Over 100 Points; 3M Earnings Top Views U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.
benzinga.com Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed; Dow rose 400 points. Hasbro surged on strong earnings and outlook, while Braze, Myriad Genetics and others gained.
benzinga.com Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
benzinga.com TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5 TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.